Sign inCreate account

Report workspace tools

NCT00933426TERMINATEDanonymous

A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases

Sponsor

Source record

M.D. Anderson Cancer Center

Phase

Source record

Phase I-II

Modality

AI-normalized

small molecule

Target

AI-normalized

Castration-Resistant Prostate Cancer

Indication / condition

AI-normalized

Prostate Cancer

Intervention

Source record

Lenalidomide, Paclitaxel

Source & freshness

Source record

NCT ID

NCT00933426

Original source

ClinicalTrials.gov

Source last updated

Oct 26, 2016

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00933426

Title

A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases

Sponsor

M.D. Anderson Cancer Center

Status

TERMINATED

Phase

Phase I-II

Condition raw

Prostate Cancer

Condition normalized

Prostate Cancer

Modality raw

Prostate Cancer

Modality normalized

small molecule

Target raw

Castration-Resistant Prostate Cancer

Target normalized

Castration-Resistant Prostate Cancer

Interventions

Lenalidomide, Paclitaxel

Public preview

Source record

This clinical trial aimed to evaluate the safety and efficacy of lenalidomide in combination with paclitaxel for men with castration-resistant prostate cancer. The study was conducted by M.D. Anderson Cancer Center and sponsored by Celgene Corporation. It was terminated early due to slow patient accrual.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Modular Phase I-II Trial of Lenalidomide and Paclitaxel in Men With Castration-Resistant Prostate Cancer and Lymph-Node Dominant Metastases

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00933426

Status

TERMINATED

Phase

Phase I-II

Sponsor

M.D. Anderson Cancer Center

Executive brief

Investment-Ready Snapshot

This clinical trial aimed to evaluate the safety and efficacy of lenalidomide in combination with paclitaxel for men with castration-resistant prostate cancer. The study was conducted by M.D. Anderson Cancer Center and sponsored by Celgene Corporation. It was terminated early due to slow patient accrual.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 26, 2016
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00933426

Indication

Prostate Cancer

Modality

small molecule

Target

Castration-Resistant Prostate Cancer

Intervention

Lenalidomide, Paclitaxel

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.